Screening and comorbidity of clinical levels of fear of cancer recurrence

摘要: The prevalence of clinical levels fear cancer recurrence (FCR) in survivors is unknown, which may be partly explained by the lack an assessment method that would make it possible to distinguish between normal and FCR. Moreover, despite apparent overlap FCR manifestations some psychiatric disorders, no study has yet evaluated comorbidity goals this were assess capacity Fear Cancer Recurrence Inventory severity subscale, consider a shorter form FCRI (FCRI-SF), screen for FCR, its comorbidity. Sixty French-Canadian (73 % those eligible) who had been treated within past 4 years localized breast, prostate, lung, or colorectal randomly selected. Participants administered interview assessing Structured Clinical Interview DSM-IV, self-report scales. A cutoff score 13 higher on FCRI-SF was associated with optimal sensitivity (88 %) specificity (75 %) rates screening significantly more likely meet criteria current disorder (60 %) than patients nonclinical (29 %). Anxiety disorders tended most common comorbid disorders. allows rapid effective condition significant